POst-Prostatectomy Ablative Radiation Therapy

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04831970

POPART

Ages 18-90
Male

Study Summary

The use of hypofractionated radiotherapy for prostate cancer has matured to a point that in current guidelines extremely hypofractionated image-guided IMRT regimens (6 Gy per fraction or greater) can be considered an alternative to conventionally fractionated regimens at clinics with appropriate technology, physics and clinical expertise. The delivery of fewer and larger fractions with hypofractionation compared to conventional radiotherapy might effectively improve the therapeutic ratio while maintaining isoeffective tumour doses, thus, shortening overall treatment time. In the present study, patients will undergo postoperative image-guided SBRT by means of volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with state-of-the-art treatment-planning and quality assurance procedures. Normal tissue sparing and delivery accuracy are accomplished by the use of devices that ensure stability and beam location reproducibility. The primary endpoint is to evaluate the cumulative incidence of treatment related toxicities and adverse events in the acute (< 90 days from the end of treatment) and late (> 90 days) setting.

Eligibility Criteria

Inclusion

INCLUSION CRITERIA

Adenocarcinoma of the prostate treated with radical prostatectomy (any type of radical prostatectomy is permitted including retropubic, perineal, laparoscopic or robotically assisted; there is no time limit for the date of radical prostatectomy).
Pathologic T3N0/Nx disease or pathologic T2N0/Nx disease, with or without a positive prostatectomy surgical margin
Post-radical prostatectomy PSA of ≥ 0.1 - < 2.0 ng/mL.
Clinical local relapse assessed by Magnetic Resonance Imaging (MRI) of the pelvis
ECOG performance status of 0-1
No distant metastases at restaging (in case of biochemical failure), within 60 days prior to registration
Patients can be on androgen deprivation therapy
Ability to understand and willingness to sign a study-specific informed consent prior to study entry

EXCLUSION CRITERIA

N1 and or M1 patients
Prior radiation of any kind to the prostate gland or pelvis
Prior brachytherapy is not allowed
History of inflammatory colitis or other active severe comorbidities
Patients who are on immunosuppressant medication

Study Design

April 15, 2021

December 31, 2026

Study Description

In this observational prospective trial eligible patients are those with adverse pathological features or rising PSA after radical prostatectomy proposed for receiving 31 Gy in 5 sessions each of 6.2 Gy to the prostatic bed delivered in one week, and up to 32.5 Gy in 5 sessions each of 6.5 Gy delivered in one week, respectively, in case of clinical relapse.

Patients will be treated by means of image guided volumetric modulated radiotherapy (IGRT-VMAT). A real time non-ionizing target monitoring might be used to account for intra-fractional errors, if deemed appropriate. Whether the dose constraints to the normal tissues are at risk, these will be prioritised over the prescription dose to the target. The primary endpoint of the trial is to assess the treatment related toxicity measured by the CTCAE v5.0. Secondary endpoints are quality of life in different domains (sexual, rectal , urinary) and biochemical outcome.

Patients will be followed at approximately one month, then every 3 months for the first 12 months and every 6 months thereafter. Quality of Life will be prospectively evaluated through validated tools (ECOG, EPIC, IIEF-5, ICIQ-SF) at various timepoints. Percentage or total mean score will be reported according to the questionnaires, whether they grade values in a scale or use descriptive statistics. Kaplan-Meier curve analysis of biochemical relapse free survival (b-RFS) at 2 and 5-year bRFS for all patients will be estimated.

Connect with a study center

Radiation Oncology, Humanitas Cancer Center (Humanitas University)
Rozzano, MI 20089
Italy
Site Not Available
Radiation Oncology, ASST Monza (University of Milan Bicocca)
Monza, 20900
Italy
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.